|
|
Article: Alprostadil Cream treatment for female sexual arousal disorder to be presented.
- Article from:
- Biotech Business Week
- Article date:
- September 20, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 SEP 20 - (NewsRx.com & NewsRx.net) -- NexMed, Inc., (NASDAQ:NEXM) announced that it will present the new findings of a pilot clinical study conducted offshore, entitled "A Pilot Clinical Study of a Topical Alprostadil Cream for the Treatment of Female Sexual Arousal Disorder (FSAD)."
The presentation will take place at the Annual Meeting of the International Society for the Study of Women's Sexual Health on October 28-31, 2004, in Atlanta, Georgia. Femprox is NexMed's proprietary FSAD treatment under development and incorporates alprostadil (PGE) with the patented NexACT technology.
This was a randomized, placebo-controlled, double-blind, crossover ...